165 related articles for article (PubMed ID: 27638929)
1. Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.
Ardill JE; Johnston BT; McCance DR; Eatock M
Ann Clin Biochem; 2017 Mar; 54(2):297-301. PubMed ID: 27638929
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine tumours of the small intestine.
Strosberg J
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917
[TBL] [Abstract][Full Text] [Related]
3. Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis.
Ardill JE; McCance DR; Stronge WV; Johnston BT
Ann Clin Biochem; 2016 Mar; 53(Pt 2):259-64. PubMed ID: 26038607
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
6. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
7. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
8. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel.
Woltering EA; Voros BA; Thiagarajan R; Beyer DT; Ramirez RA; Wang YZ; Mamikunian G; Boudreaux JP
Pancreas; 2018 Aug; 47(7):843-848. PubMed ID: 29939909
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
10. Management of midgut carcinoids.
Akerström G; Hellman P; Hessman O; Osmak L
J Surg Oncol; 2005 Mar; 89(3):161-9. PubMed ID: 15719373
[TBL] [Abstract][Full Text] [Related]
11. [Neuroendocrine tumors of gastrointestinal tract in own material].
Myśliwiec P; Gryko M; Kedra B; Zalewski B; Kowalska I; Myśliwiec J
Endokrynol Pol; 2006; 57(2):166-71. PubMed ID: 16773593
[TBL] [Abstract][Full Text] [Related]
12. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
13. A jejunal stromal tumour in a patient with metastatic neuroendocrine cancer of unknown origin; a rare coexistence, diagnostic and therapeutic challenge.
El Ali Z; Iwanik K; Sowiński J; Swora E; Grzymislawski M
Endokrynol Pol; 2009; 60(3):216-20. PubMed ID: 19569023
[TBL] [Abstract][Full Text] [Related]
14. Clinical scenario 2: Exploring treatment options for patients with symptomatic, progressive GEP-NETs.
Pape UF
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):20-2. PubMed ID: 25768106
[No Abstract] [Full Text] [Related]
15. Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.
Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA
Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678
[TBL] [Abstract][Full Text] [Related]
16. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
[TBL] [Abstract][Full Text] [Related]
17. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).
de Herder WW
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895
[TBL] [Abstract][Full Text] [Related]
18. Malignant carcinoid in two brothers.
Kinova S; Duris I; Kovacova E; Stvrtina S; Galbavy S; Makaiova I
Bratisl Lek Listy; 2001; 102(5):231-4. PubMed ID: 11725374
[TBL] [Abstract][Full Text] [Related]
19. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action.
Imam H; Gobl A; Eriksson B; Oberg K
Anticancer Res; 1997; 17(6D):4659-65. PubMed ID: 9494585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]